Biomarker Correlates and Clinical Activity of Cevostamab in Patients (pts) with Triple-Class Refractory Multiple Myeloma (MM) Who Have Received ≥1 Prior B-Cell Maturation Antigen (BCMA)-Targeted Bispecific Antibody (BsAb): Results from the Phase I/II CAMMA 2 Study
Year: 2024
Type: conference-abstract
Source: Blood
Authors: Michel Delforge, Joshua Richter, Yael C. Cohen, Paolo Corradini, Douglas W Sborov, Alexander M. Lesokhin, Jesus G Berdeja, Moshe E Gatt, Laura Paris, Laura Rosinol Dachs, Hang Quach, Manisha Kanwar, Olivier Catalani, Paresh Sewpaul, Elisabeth Wassner-Fritsch, Ameet Mishra, Kerstin Trunzer, Shaji Kumar
Institutions: Universitair Ziekenhuis Leuven, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Tel Aviv University, Tel Aviv Sourasky Medical Center, University of Milan, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Utah, Huntsman Cancer Institute, Memorial Sloan Kettering Cancer Center, Tennessee Oncology, Hebrew University of Jerusalem, Hadassah Medical Center, Ospedale Papa Giovanni XXIII, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, The University of Melbourne, St Vincent's Hospital Melbourne, Roche (United Kingdom), Roche (Switzerland), Mayo Clinic
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4405038541